is revumenib listed on nccn guidelines - SERP Analysis

https://ir.syndax.com/news-releases/news-release-details/syndax-highlights-recent-accomplishments-and-anticipated-2025

https://www.nccn.org/patients/guidelines/content/PDF/aml-patient.pdf

https://revuforjhcp.com/

https://fm.formularynavigator.com/FormularyNavigator/DocumentManager/Download?clientDocumentId=ZxS3eo-yBUazaZt1SO_xMA

https://www.jmcp.org/doi/10.18553/jmcp.2025.25027

https://www.ajmc.com/view/revumenib-shows-efficacy-in-patients-with-aml-and-genetic-alterations

https://www.eocco.com/-/media/EOCCO/PDFs/Formulary/EOCCOrevumenib-RevuforjPolicy.pdf

https://www.hoparx.org/latest-news/pharmacists-application-to-practice-revumenib/

https://www.prnewswire.com/news-releases/syndax-highlights-recent-accomplishments-and-anticipated-2025-milestones-at-the-43rd-annual-jp-morgan-healthcare-conference-302348949.html

https://cms.syndax.com/wp-content/uploads/2025/03/Abraham_2025-ISPOR_AUGMENT-101-KMT2Ar-HEOR-BIM_Poster_Final.pdf

https://www.onclive.com/view/updated-nccn-guidelines-recommend-naxitamab-in-high-risk-neuroblastoma

https://www.cancernetwork.com/view/nccn-expands-genetic-risk-assessment-guidelines-to-include-additional-tumor-types

https://clinicaltrials.gov/study/NCT04065399?term=AREA%5BConditionSearch%5D(%22Myeloid%20Leukemia%22)%20AND%20AREA%5BInterventionSearch%5D(%22Isavuconazole%22)&rank=5

https://www.bloodcancerstoday.com/post/expert-panel-updates-nccn-guidelines-on-pediatric-all-with-focus-on-t-all

https://www.centerwatch.com/clinical-trials/listings/NCT04065399/a-study-of-revumenib-in-r-r-leukemias-including-those-with-an-mllkmt2a-gene-rearrangement-or-npm1-mutation

https://firstwordpharma.com/story/5939250

https://www.oregon.gov/oha/HSD/OHP/SiteAssets/Lists/Accordions/AllItems/Acute%20Lymphoblastic%20Leukemia%20NCCN.pdf

https://www.onclive.com/view/olverembatinib-added-to-nccn-guidelines-for-cml

https://www.nccn.org/patients/guidelines/content/pdf/ped_all_patient.pdf

https://www.jmcp.org/doi/abs/10.18553/jmcp.2025.25027

https://www.ajmc.com/view/nccn-guidelines-prioritize-quad-therapy-in-multiple-myeloma

https://cancerletter.com/clinical-roundup/20241122_7a/

https://www.nccn.org/guidelines/category_1

https://jnccn.org/abstract/journals/jnccn/23/2/article-p41.xml

https://www.cancernetwork.com/view/nccn-issues-guidelines-stem-cell-transplantation

https://www.stocktitan.net/news/SNDX/syndax-highlights-recent-accomplishments-and-anticipated-2025-p6ar19pup76j.html

https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1411

https://www.sec.gov/Archives/edgar/data/1395937/000095017025030392/sndx-ex99_1.htm

https://www.oncokb.org/news

https://emedicine.medscape.com/article/207631-guidelines

https://www.imbruvicahcp.com/wm/support-and-resources/nccn-guidelines

https://ashpublications.org/blood/article/143/1/11/498663/How-I-treat-refractory-and-relapsed-acute-myeloid

https://cllsociety.org/2025/03/understanding-nccn-guidelines-for-cll-sll-as-a-patient/

https://med.stanford.edu/classicuitesting/lists/clinical-trials/list-by-keyword.html?ctid=NCT04065399&conditionId=&serviceLineId=&condition=&alpha=a

https://www.theoncologynurse.com/issue-archive/2024/february-2024-vol-17-no-1/single-drug-targeted-therapy-may-improve-proportion-of-patients-with-hard-to-treat-leukemias-proceeding-to-transplant

https://vchcptest.ventura.org/providers/docs/padg/Revuforj.pdf

https://menininsights.com/wp-content/themes/syndax/SYNUS220015_Augment-101_Trial_Card_Update_FSU_v2_CF%5B98%5D.pdf

https://trialfinder.panfoundation.org/en-US/trial/listing/211699

https://www.healthnet.com/content/dam/centene/policies/pharmacy-policies/CP.PHAR.707.pdf

https://cme.ahn.org/sites/default/files/AML%20Treatment%20-%20NCCN%20Guidelines.pdf

https://pmc.ncbi.nlm.nih.gov/articles/PMC4161234/

https://www.researchgate.net/publication/388923968_Pediatric_Acute_Lymphoblastic_Leukemia_Version_22025_NCCN_Clinical_Practice_Guidelines_In_Oncology

https://www.onkopedia-guidelines.info/de/wissensdatenbank/wissensdatenbank/akute-myeloische-leukaemie/v208_lars_bullinger_therapiekonzepte-bei-juengeren-aml-patienten.pdf/%40%40download/file/V208_Lars_Bullinger_Therapiekonzepte-bei-j%C3%BCngeren-AML-Patienten.pdf

https://bosulif.pfizerpro.com/about/nccn-guidelines

https://www2.tri-kobe.org/nccn/guideline/hematologic/english/aml.pdf

https://www.targetedonc.com/view/nccn-adds-rylaze-to-clinical-practice-guidelines-for-acute-lymphoblastic-leukemia

https://ce.mayo.edu/sites/default/files/US-ELZ-00835%20NCCN%20Guidelines%20Flashcard.pdf

https://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=2430

https://www.calquencehcp.com/cll/nccn-guidelines.html

https://revuforjhcp.com/efficacy/

https://www.oncokb.org/gene/NPM1/Deletion/Acute%20Myeloid%20Leukemia

https://www.valuebasedcancer.com/issues/2023/june-2023-vol-14-no-3/new-nccn-guidelines-for-cll-sll-include-second-generation-btk-inhibitors

https://wiki.shawnyu.org/lib/exe/fetch.php?media=public:nccn:ped_all.pdf

https://www.iononline.com/-/media/assets/ion/pdf/precision-medicine-by-partner/astellas/077-1170-pm_xospata-nccn-guidelines-flashcard_electronic-5.pdf?la=en&hash=F3B8F8C7A3C7621118C7A8D8AF22C79E04E1F050

https://med.stanford.edu/transplantation/Research/ClinicalResearch.html?ctid=NCT04065399&conditionId=21&serviceLineId=&condition=Leukemia&alpha=a

https://www.cancer.gov/research/participate/clinical-trials/intervention/revumenib?pn=1

https://mcgs.bcbsfl.com/MCG?mcgId=09-J3000-65&pv=false

https://www.amazon.com/Guidelines-Patients%C2%AE-Acute-Lymphoblastic-Leukemia/dp/1954190905

https://reference.medscape.com/viewarticle/995535

https://cllsociety.org/2022/11/nccn-revamps-treatment-preferences-in-cll-sll/

https://www.thd.org.tr/thdData/userfiles/file/NCCN-CML-2022-v2.pdf

https://www.vyxeospro.com/files/VYXEOS-NCCN-Guidelines-Flashcard.pdf

https://pubmed.ncbi.nlm.nih.gov/31200351/

https://oncolife.com.ua/doc/nccn/Acute_Myeloid_Leukemia.pdf

https://theoncologynurse.com/categories/4105:leukemia

https://www2.tri-kobe.org/nccn/guideline/hematologic/english/all.pdf

https://www.researchgate.net/figure/Duration-of-treatment-Treatment-course-of-revumenib-in-patients-with-KMT2Ar-relapsed-or_fig2_382999089

https://www.oncnursingnews.com/view/updated-nccn-guidelines-recommend-imetelstat-to-treat-anemia-in-lower-risk-mds

https://www.studocu.com/pe/document/universidad-cesar-vallejo/medicina-interna/nccn-guidelines-for-acute-lymphoblastic-leukemia-v32024-key-updates-and/130350214

https://www.inqovi.com/hcp/MDS-nccn-guidelines

https://www.hematologyandoncology.net/archives/march-2017/the-new-nccn-guidelines-for-the-management-of-myelofibrosis/

https://www.valuebasedcancer.com/issues/2023/june-2023-vol-14-no-3/3389:new-nccn-guidelines-for-cll-sll-include-second-generation-btk-inhibitors

https://www.clonoseq.com/wp-content/uploads/2021/08/NCCN_Guidelines_Adult_ALL_PM-US-cSEQ-0654.pdf

https://www.poijaya.org/wp-content/uploads/2021/03/NCCN-Acute-Myeloid-Leukemia.pdf

https://www.targetedonc.com/view/nccn-adds-olverembatinib-in-newest-guidelines-on-cml-management

https://mdanderson.elsevierpure.com/en/publications/acute-myeloid-leukemia-version-22021-featured-updates-to-the-nccn

https://www.amazon.com/Guidelines-Patients%C2%AE-Chronic-Lymphocytic-Leukemia/dp/1965864015

https://www.mskcc.org/news/promising-new-type-drug-aggressive-leukemia

https://ctv.veeva.com/study/a-study-of-sndx-5613-in-r-r-leukemias-including-those-with-an-mllr-kmt2a-gene-rearrangement-or-npm1

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-revumenib-relapsed-or-refractory-acute-leukemia-kmt2a-translocation

https://www.nccn.org/guidelines/guidelines-detail

https://oncpracticemanagement.com/articles/updated-nccn-treatment-guideline-for-cml-establishes-criteria-for-stopping-tki-therapy

https://www.cancer.gov/news-events/cancer-currents-blog/2023/revumenib-menin-inhibitor-advanced-aml

https://ufhealth.org/clinical-trials/a-study-of-revumenib-in-combination-with-chemotherapy-for-patients-diagnosed-with-relapsed-or-refrac

https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1427

http://journals.lww.com/oncology-times/blog/fdaactionsandupdates/pages/post.aspx?PostID=459

https://www.globenewswire.com/news-release/2025/03/03/3035483/0/en/Syndax-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html

https://www.nccn.org/guidelines/guidelines-with-evidence-blocks

https://www.ons.org/publications-research/voice/news-views/11-2024/fda-approves-revumenib-relapsed-or-refractory-acute

https://www.gurufocus.com/news/2653956/syndax-highlights-recent-accomplishments-and-anticipated-2025-milestones-at-the-43rd-annual-jp-morgan-healthcare-conference

https://www.pharmacytimes.com/view/in-a-nod-to-precision-oncology-the-fda-approves-revumenib

https://www.oncologynewscentral.com/article/revumenib-shows-impressive-results-in-r-r-acute-leukemia-trial

https://www.youtube.com/watch?v=Lbd-rmXr-JA

https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1483

https://www.pharmacytimes.com/view/fda-approves-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemia

https://www.oncnursingnews.com/view/ropeginterferon-alfa-2b-listed-in-nccn-guidelines-as-a-preferred-polycythemia-vera-treatment

https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1478

https://www.nccn.org/patients/guidelines/content/PDF/all-patient.pdf

https://www.oncologynewscentral.com/sitemap